TRIPLE NEGATIVE BREAST CANCER

This study tests a new drug called BNT327, given with chemotherapy, for people with advanced triple-negative breast cancer that has spread. The goal is to see if the combination is safe and shrinks tumors. About 83 adults will take part, and the study is currently active but not …

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This study tests whether taking enzalutamide for one year after standard treatment is practical for people with early-stage triple negative breast cancer that has androgen receptors. About 50 participants will take the drug and report on their quality of life. The main goal is to…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This early-phase study tests whether adding the drug niraparib to standard radiation therapy after surgery can help prevent triple negative breast cancer from coming back. Niraparib is a PARP inhibitor that blocks cancer cells from repairing their DNA. The study includes 21 adult…

This early-phase study tests a cancer vaccine (PVX-410) alone or with the immunotherapy drug pembrolizumab in 20 women with metastatic triple negative breast cancer who have a specific genetic marker (HLA-A2). The goal is to see if the vaccine safely boosts the immune system to f…

This study tests whether combining two drugs (niraparib and dostarlimab) with radiation therapy is safe and effective for people with metastatic triple-negative breast cancer that has not responded to immunotherapy or is PD-L1 negative. About 32 adults with this aggressive cancer…

This Phase 3 trial tests whether a new drug, datopotamab deruxtecan (Dato-DXd), given alone or with another drug (durvalumab), can help prevent breast cancer from returning in people with triple-negative breast cancer who still have cancer cells after initial treatment and surger…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This phase 2 trial tests a new immunotherapy drug called tobemstomig combined with chemotherapy (nab-paclitaxel) against the standard combination of pembrolizumab plus chemotherapy. It includes 83 people with previously untreated, PD-L1-positive, advanced triple-negative breast c…

This early-phase study tests a new drug called JANX008 in about 130 adults with advanced solid tumors, including lung, kidney, head and neck, colorectal, pancreatic, and breast cancers. The main goal is to check safety and find the right dose. Participants must have tried all sta…

This study tests the drug niraparib in 20 people whose cancer has spread to the brain or spinal cord. The goal is to see if the drug can shrink or control these tumors. Participants must have mild or no symptoms from their brain metastases and not need increasing steroids or seiz…

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This study tests two drugs, olaparib and pembrolizumab, given before standard surgery for people with triple-negative or hormone receptor-positive HER2-negative breast cancer who have specific gene mutations. The goal is to see if the combination can shrink tumors enough to impro…

This early-stage trial is testing a new drug called tuvusertib, given together with either lartesertib or avelumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body pr…

This phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This study tests two drugs, niraparib and dostarlimab, given before surgery to people with BRCA- or PALB2-mutated breast cancer. The goal is to see if this combination boosts the immune system's attack on the tumor and leads to a complete response (no cancer left at surgery). Abo…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can completely eliminate tumors in people with localized triple-negative breast cancer. About 51 women with early-stage, untreated disease will receive the combination, then…

This phase 3 trial tests a new drug called Dato-DXd against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. About 644 participants will be randomly assigned to receive either Dato-DXd or one of several chemotherapy dr…

This early-stage trial tests a new oral drug called ceralasertib, given alone or with other cancer treatments like chemotherapy or targeted drugs, in 354 adults with advanced solid tumors that no longer respond to standard care. The main goal is to check safety and find the best …

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This early-phase trial tests a dendritic cell vaccine given directly into the spinal fluid for people with breast cancer that has spread to the lining of the brain (leptomeningeal disease). The vaccine is designed to train the immune system to attack cancer cells. The main goal i…

This study tests whether adding the drug ipatasertib to standard chemotherapy and immunotherapy (atezolizumab) can improve outcomes for women with high-risk triple-negative breast cancer before surgery. About 146 women with newly diagnosed, non-metastatic tumors that are at least…

This study looks at whether women with aggressive breast cancers (triple-negative or HER2-positive) who have a complete response to chemotherapy can safely avoid sentinel lymph node biopsy. The trial will enroll 350 patients across Europe, all of whom will have breast-conserving …

This Phase 3 trial tests a new chemotherapy drug called SKB264 against standard chemotherapies in 254 people with advanced triple-negative breast cancer that has worsened after at least two prior treatments. The main goal is to see if SKB264 can delay cancer growth longer than th…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy before surgery can help the immune system fight triple-negative breast cancer more effectively. About 15 people with early-stage (stage II or III) triple-negative breast cancer will receive …

This study tests a new drug called PF-07104091 in people with advanced small cell lung cancer, ovarian cancer, or certain breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug shrinks tumors, either alone or with other…

This was a phase II trial testing a combination of three drugs—zimberelimab, domvanalimab, and sacituzumab govitecan—as a first treatment for people with advanced triple-negative breast cancer that is PD-L1 positive. The study aimed to see how well the drugs shrank tumors and how…

This phase 2 trial tests whether the number of immune cells in and around a triple-negative breast cancer tumor can help doctors personalize chemotherapy and immunotherapy. About 139 women with early-stage triple-negative breast cancer will receive standard chemotherapy drugs plu…

This phase 2 trial tests whether adding an immunotherapy drug called IRX 2 to standard pembrolizumab (Keytruda) and chemotherapy can improve outcomes for people with triple-negative breast cancer. The study involves 12 participants who receive the combination before surgery. The …

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy is safe and works for people with metastatic triple negative breast cancer, a hard-to-treat form. 29 adults with advanced cancer that had spread or could not be removed by surgery took …

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to the chemotherapy pill capecitabine helps prevent cancer from coming back in people with triple-negative breast cancer who still had cancer after initial chemotherapy and surgery. About 284 participants…

This Phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) can prevent breast cancer from returning in patients with HER2-negative breast cancer who still have cancer after initial chemotherapy. About 1,332 participants will receive either the new drug or standard…

This phase 3 study compares a new drug, BL-B01D1, to standard chemotherapy in 418 people with advanced triple-negative breast cancer that has stopped responding to taxane chemotherapy. The goal is to see if BL-B01D1 can slow cancer growth and extend survival. Participants must be…

This Phase 2 study tests a drug called zelenectide pevedotin in 66 people with advanced breast cancer that has a specific gene change (NECTIN4 amplification). The study includes two groups: one with hormone receptor-positive/HER2-negative cancer and one with triple-negative breas…

This study tests a combination of three drugs (nivolumab, bicalutamide, and ipilimumab) in 30 people with advanced HER2-negative breast cancer that has spread. The goal is to see if this chemo-free approach can control the disease for at least 24 weeks. Participants must have mea…

This trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can eliminate all signs of cancer in people with early-stage triple-negative breast cancer before they have surgery. About 31 participants with small tumors (1 to 2.5 cm) that haven't sp…

This phase 3 study compares a targeted drug called sacituzumab govitecan against standard chemotherapy in about 623 people with advanced triple-negative breast cancer that does not express PD-L1 (a protein that makes immunotherapy work). Participants either have not received prio…

This large Phase 3 trial tests whether a new combination of drugs (datopotamab deruxtecan plus durvalumab) given before and after surgery works better than the current standard treatment for people with untreated triple-negative or hormone receptor-low/HER2-negative breast cancer…

This phase II trial is testing whether giving two chemotherapy drugs, carboplatin and nab-paclitaxel, before surgery can improve outcomes for people with locally advanced or inflammatory triple negative breast cancer. The goal is to see if this approach increases the rate of comp…

This phase 2 trial is testing whether combining immunotherapy drugs (pembrolizumab, ipilimumab, nivolumab) with a freezing technique called cryoablation before standard surgery can improve outcomes for women with triple-negative breast cancer. The study enrolls 51 women who have …

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug targets and kills cancer cells by attaching to them and blocking growth. About 11…

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) for people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. About 14 participants will receiv…

This early-phase trial tests whether adding a single, focused dose of radiation before surgery can make the immunotherapy drug pembrolizumab work better in people with early-stage breast cancer. About 27 participants will receive both treatments, then have surgery to see if the t…

This trial is testing whether giving a small dose of targeted radiation to a part of the breast tumor before standard chemotherapy can help the immune system fight the cancer more effectively. The study includes 40 people with high-risk or locally advanced breast cancer. After ra…

This phase 2 trial is testing whether combining an experimental pill (CFI-400945) with an immunotherapy drug (durvalumab) can shrink tumors in 15 women with advanced triple negative breast cancer that has spread or cannot be removed. The study measures how many participants see t…

This study tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) plus chemotherapy in 81 women with triple negative breast cancer. It includes two groups: those with early-stage cancer and those with advanced (metastatic) cancer. The goal is to see if the …

This study tests whether giving stereotactic body radiotherapy (SBRT) to growing metastatic tumors can delay overall cancer progression. About 107 adults with triple-negative breast cancer or non-small cell lung cancer that has started to grow in a few spots will receive SBRT or …

This study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goa…

This phase 3 trial tests a new drug called FDA018-ADC against standard chemotherapy in 350 people with advanced triple-negative breast cancer that has worsened after taxane treatment. The study compares how long the cancer stays under control and overall survival. Participants ar…

This early-phase study tests a new drug, DKY709, alone or with another drug (PDR001) in people with advanced solid tumors like lung cancer, melanoma, and breast cancer. The main goal is to find a safe dose and check for side effects. About 98 adults whose cancer worsened after st…

This early-phase trial tests a new drug called PEP-010 in people with advanced solid tumors that have spread. The study checks if PEP-010 is safe alone or with chemotherapy (paclitaxel or gemcitabine). About 57 adults with metastatic pancreatic, ovarian, or other solid cancers wi…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This study tests a combination of two drugs, ribociclib and bicalutamide, in people with advanced triple-negative breast cancer that has a specific marker (androgen receptor). The goal is to see if the combo can shrink tumors or stop them from growing. 37 participants are enrolle…

This study tests a new combination of two drugs (Debio 0123 and sacituzumab govitecan) in people with advanced breast cancer that has not responded to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 76 adults with triple-n…

This early-phase study tests a new drug called GH2616 in about 126 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a protein (KIF18A) that helps cancer cells divide, which may slow or stop tumor growth. The main goals are …

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…

This study tests a new drug, DS-1062a, in people with advanced solid tumors like lung and breast cancer that haven't responded to other treatments. It's the first time this drug is being used in humans, so the main goals are to check safety, find the right dose, and see if it hel…

This early-phase trial tests a new antibody drug called IMT-009, given alone or with the cancer pill fruquintinib, in about 67 people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand si…

This study is for people with a certain type of breast cancer (HER2-negative) that has spread to lymph nodes. It tests giving a mix of chemotherapy, an immunotherapy drug (pembrolizumab), and different doses of radiation before surgery. The goal is to see if this approach helps t…

This study tests a combination of three drugs—cisplatin, romidepsin, and nivolumab—in people with advanced triple-negative breast cancer or BRCA-related breast cancer that has spread. The goal is to see if the combination can shrink tumors and control the disease. About 51 partic…

This early-phase study tests a new drug called BL-M02D1 in people with advanced triple negative breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors.…

This phase 3 trial tests whether combining sacituzumab govitecan (Trodelvy) with pembrolizumab (Keytruda) works better than standard chemotherapy plus pembrolizumab for people with advanced triple-negative breast cancer that has a protein called PD-L1. About 443 participants who …

This phase 2 trial is testing whether adding the immunotherapy drug cemiplimab (Libtayo) to standard chemotherapy can eliminate more cancer before surgery in people with high-risk or locally advanced breast cancer. The study enrolls 36 participants with either hormone receptor-po…

This study was designed to test a combination of two drugs, Ezabenlimab and BI907828, in people with advanced solid tumors like sarcoma, lung cancer, and breast cancer. The goal was to see if the treatment could control the disease for at least 24 weeks. However, the trial was wi…

This pilot study tests a new type of breast scan called DBT-TOBI, which combines 3D mammography with light-based imaging. Researchers want to see if it can predict how well breast cancer responds to chemotherapy early in treatment. The study involves 30 women with HER2+ or triple…

This pilot study aimed to see if contrast-enhanced ultrasound (CEUS) could predict how well triple-negative breast cancer patients respond to chemotherapy and immunotherapy. Researchers planned to measure tumor volume and blood flow changes with CEUS before and during treatment. …

This study looks at whether a breast MRI-guided biopsy can accurately tell if a woman's breast cancer has completely disappeared after chemotherapy. Researchers will enroll 31 women whose tumors are no longer visible on MRI after treatment. If the biopsy correctly identifies a co…

This observational study tracks how doctors treat advanced triple-negative breast cancer in Canada, the UK, France, and Spain. Researchers will look at real-world data from 760 patients to understand treatment patterns and outcomes. No new drugs are being tested—the goal is to ga…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at whether certain blood cell counts and tumor-infiltrating lymphocytes can help predict if triple negative breast cancer will come back. Researchers will collect blood samples from 90 women after radiation and at the time of any first recurrence. The goal is to …

This study looks at whether measuring certain inflammatory proteins (cytokines) in the blood during radiotherapy can help predict which triple-negative breast cancer patients are likely to have their cancer come back. Researchers will take blood samples from 15 women before and d…

This trial was designed to test whether adding aspirin to the immunotherapy drug avelumab could help the immune system fight triple-negative breast cancer. Participants would have received either avelumab alone or with aspirin for about 18 days, with biopsies and blood tests to m…

This study looks at whether a set of proteins in the blood can predict if triple-negative breast cancer will come back after treatment. Researchers will follow 90 women and test their blood at several time points. The goal is to find a simple way to identify patients who need clo…